|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Captopril#Adult Indications and Dosage]] |
| {{Captopril}}
| |
| {{CMG}}; {{AE}} {{AM}}
| |
|
| |
|
| ==Indications and Usage==
| | [[Category: Cardiovascular Drugs]] |
| | | [[Category: Drug]] |
| ====Hypertension====
| | [[Category:ACE inhibitors]] |
| | |
| Captopril tablets, USP are indicated for the treatment of [[hypertension]].
| |
| | |
| In using captopril, consideration should be given to the risk of [[neutropenia]]/[[agranulocytosis]].
| |
| | |
| Captopril may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. In patients with [[impaired renal function]], particularly those with [[collagen vascular disease]], captopril should be reserved for [[hypertensive]]s who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations.
| |
| | |
| Captopril is effective alone and in combination with other antihypertensive agents, especially [[thiazide]]-type [[diuretics]]. The [[blood pressure]] lowering effects of captopril and [[thiazides]] are approximately additive.
| |
| | |
| ====Heart Failure====
| |
| | |
| Captopril tablets, USP are indicated in the treatment of [[congestive heart failure]] usually in combination with [[diuretics]] and [[digitalis]]. The beneficial effect of captopril in [[heart failure]] does not require the presence of [[digitalis]], however, most controlled clinical trial experience with captopril has been in patients receiving [[digitalis]], as well as [[diuretic]] treatment.
| |
| | |
| ====Left Ventricular Dysfunction After Myocardial Infarction====
| |
| | |
| Captopril tablets, USP are indicated to improve survival following [[myocardial infarction]] in clinically stable patients with [[left ventricular dysfunction]] manifested as an [[ejection fraction]] ≤40% and to reduce the incidence of overt [[heart failure]] and subsequent hospitalizations for [[congestive heart failure]] in these patients.
| |
| | |
| ====Diabetic Nephropathy====
| |
| | |
| Captopril tablets, USP are indicated for the treatment of [[diabetic nephropathy]] ([[proteinuria]] >500 mg/day) in patients with [[type I insulin-dependent diabetes mellitus]] and [[retinopathy]]. Captopril decreases the rate of progression of [[renal insufficiency]] and development of serious adverse clinical outcomes (death or need for renal transplantation or dialysis).
| |
| | |
| In considering use of captopril, it should be noted that in controlled trials [[ACE inhibitors]] have an effect on blood pressure that is less in black patients than in non-blacks. In addition, ACE inhibitors (for which adequate data are available) cause a higher rate of [[angioedema]] in black than in non-black patients.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = CAPTOPRIL (CAPTOPRIL ) TABLET CAPTOPRIL TABLET [APOTEX CORP.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2c0f1ee3-b2b7-a1bc-059a-d65bea6cd0ef | publisher = | date = | accessdate =}}</ref>
| |
| | |
| ==References==
| |
| | |
| {{Reflist}}
| |
| | |
| {{FDA}}
| |
| | |
| [[Category:Cardiovascular Drugs]] | |
| [[Category:Drugs]] | |